Elan announces approval of new versions of Skelaxin and tizanidine
By wire reports
Posted 9:44AM on Wednesday, September 4, 2002
DUBLIN, Ireland - Elan Corporation, plc today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for an 800 mg strength Skelaxin (metaxalone) tablet and a new drug application (NDA) for 2 mg, 4 mg and 6 mg tizanidine hydrochloride in capsule presentations. <br>
<br>
The capsule presentation represents a new formulation of Elan's currently marketed Zanaflex tablets. <br>
<br>
Skelaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. Tizanidine is indicated for the management of spasticity. <br>
<br>
